.png)
2 hours ago
Novo Nordisk A/S (NYSE:NVO) announced that its weight-loss drug Wegovy has reached 1.2 million U.S. patients. Of these, 55 million individuals are covered by insurance, and over 80% pay less than $25 per prescription, according to statements made during the company’s fourth-quarter 2024 earnings call.
What Happened: The Danish pharmaceutical giant faces potential challenges as semaglutide-containing products, including Wegovy, Ozempic, and Rybelsus, have been selected for the second round of Centers for Medicare and Medicaid Services (CMS) price negotiations.
The negotiations are set to conclude in early November, with maximum fair prices to be published by month-end and implementation scheduled for Jan.1, 2027.
“We oppose government price setting like we ...
